This report was first published by Endpoints News. To see the original version, click here
Vyne Therapeutics will hand its Nasdaq spot to RTW’s Yarrow Bioscience in a reverse merger that will also bring a $200 million cash infusion into the biotech.
The all-stock transaction announced Wednesday will give Yarrow stockholders 97% of the combined company, with pre-merger Vyne shareholders getting the remainder. The additional funding will come from investors that include RTW, OrbiMed, Janus Henderson and venBio Partners.
您已阅读27%（521字），剩余73%（1417字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。